GlycoErase™ AGL Knockout HEK293 Cell Line

GlycoErase™ AGL knockout HEK293 cell line is a human embryonic kidney (HEK293) model in which AGL expression has been eliminated. AGL encodes the glycogen debranching enzyme with both 4-alpha-glucotransferase and amylo-1,6-glucosidase activity, which is essential for glycogen breakdown. Deficiency of this enzyme leads to glycogen storage disorders and altered energy balance. The knockout of AGL in the HEK293 background provides a human-based platform for exploring glycogen metabolism, cellular energy utilization, and metabolic stress responses, while enabling applications in disease modeling, therapeutic testing for glycogen storage disorders, and carbohydrate metabolism studies.

KO Cell Lines

Human

Epithelial-like, adherent

1:2~1:4

HEK293

Embryonic kidney

>90%

The sterility test indicated an absence of microbial growth.

STR identification

Negative

Negative for HIV, HBV and HCV.

We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.

PCR, Sanger Sequencing

FBS & Penicillin/Streptomycin & Proline & RPMI

Functional assay

1 M cells/vial*2

Frozen

Dry ice

Made to order

Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.

This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

AGL

Amylo-Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase

GDE

1p21.2

Glycogen debranching enzyme has two catalytic functions-4-alpha-glucotransferase and amylo-1,6-glucosidase-at distinct sites. It participates in glycogen breakdown, and mutations cause glycogen storage disease with variable clinical presentations, possibly due to tissue-specific splicing. Multiple isoforms exist.